免疫耐受期慢性乙型肝炎的研究进展  

Research Progress of Chronic Hepatitis B in Immune Tolerance Stage

作　　者：谭伟 周杰斌 TAN Wei;ZHOU Jiebin(The Second Affiliated Hosptital,University of South China,Hengyang 421001,China;不详)

机构地区：[1]南华大学附属第二医院,湖南衡阳421001

出　　处：《中外医学研究》2023年第26期181-184,共4页CHINESE AND FOREIGN MEDICAL RESEARCH

摘　　要：慢性乙型肝炎病毒(HBV)感染是全球卫生领域的重要挑战和人类健康的重大威胁,尤其是免疫耐受期慢性乙型肝炎(IT-CHB)患者在治疗上存在较大的困难和争议。IT-CHB患者以高病毒载量、低免疫应答为主要特征,既往认为IT-CHB患者疾病进展轻微、抗病毒治疗应答率低、停药后效果难以持续且容易发生反弹,多不主张积极治疗。持续的高病毒载量是肝癌发生的重要危险因素,通过积极抗病毒治疗以最大限度地抑制病毒复制、降低肝癌的发生率是全球公认的治疗目标。在这一背景下,本文综述了IT-CHB的概述、现状,治疗领域面临的挑战和启示,以期加深对IT-CHB的认识。Chronic hepatitis B virus(HBV)infection is an important challenge in the field of global health and a major threat to human health,especially the treatment of patients with chronic hepatitis B in the immune tolerance stage(IT-CHB)is difficult and controversial.Patients with IT-CHB are mainly characterized by high viral load and low immune response.In the past,it was believed that patients with IT-CHB had mild disease progression,low response rate to antiviral therapy,difficult to sustain the effect after drug withdrawal and prone to rebound,and most of them did not advocate active treatment.Persistent high viral load is an important risk factor for liver cancer,and active antiviral therapy to a maximize inhibition the virus replication and reduce the incidence of liver cancer is a globally recognized therapeutic goal.In this context,this paper reviews the overview,current situation,challenges and inspirations of treatment field of IT-CHB,in order to deepen the understanding of IT-CHB.

关 键 词：乙型肝炎病毒 免疫耐受期 研究进展 

分 类 号：R512.62[医药卫生—内科学]